Modalis Therapeutics (4883.T) Stock Price
Modalis Therapeutics Price
Revenue at Modalis Therapeutics has contracted by 11.3% per year over the past 4 years to 40.50 M JPY. Modalis Therapeutics's net margin stands at -6,673.4%, down from -333.7% several years earlier.
Modalis Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Modalis Therapeutics business model & stock analysis
Frequently asked questions about Modalis Therapeutics
5 analysts currently rate the Modalis Therapeutics stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Modalis Therapeutics to generate revenue of 800.00 M JPY and earnings per share of -21.83 JPY.
Converted at the current exchange rate, the Modalis Therapeutics share trades at 0.16 EUR (29.00 JPY).
The expected revenue of Modalis Therapeutics is 800.00 M JPY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Modalis Therapeutics is -1.94 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Modalis Therapeutics is currently -1.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Modalis Therapeutics stock.
The price-to-sales ratio (P/S) of Modalis Therapeutics is currently 3.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Modalis Therapeutics stock.
The Eulerpool Quality Score for Modalis Therapeutics is 1/10.
The ISIN of Modalis Therapeutics is JP3922600006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Modalis Therapeutics is 4883.T. The ticker symbol is used to trade Modalis Therapeutics shares on the stock exchange.
Modalis Therapeutics stock
Modalis Therapeutics Peer Group
Modalis Therapeutics FIGI
All fundamentals and in-depth analysis of Modalis Therapeutics
Our stock analysis for Modalis Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Modalis Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.